These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11594558)

  • 1. Ovulation induction disrupts luteal phase function.
    Tavaniotou A; Smitz J; Bourgain C; Devroey P
    Ann N Y Acad Sci; 2001 Sep; 943():55-63. PubMed ID: 11594558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ovarian stimulation on corpus luteum function and embryonic implantation.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    J Reprod Immunol; 2002; 55(1-2):123-30. PubMed ID: 12062827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on the changes of gonadotropin releasing hormone agonist in pinopodes].
    Zhou WQ; Jiang YL; Tang HB; Gao HY; Zhuang YY; Xia F; Mao CP; Zhu CR
    Zhonghua Fu Chan Ke Za Zhi; 2017 Aug; 52(8):539-544. PubMed ID: 28851171
    [No Abstract]   [Full Text] [Related]  

  • 6. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
    Gizzo S; Andrisani A; Esposito F; Noventa M; Di Gangi S; Angioni S; Litta P; Gangemi M; Nardelli GB
    Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles.
    Simon C; Oberyé J; Bellver J; Vidal C; Bosch E; Horcajadas JA; Murphy C; Adams S; Riesewijk A; Mannaerts B; Pellicer A
    Hum Reprod; 2005 Dec; 20(12):3318-27. PubMed ID: 16085660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.
    Roseff SJ; Kettel LM; Rivier J; Burger HG; Baulieu E; Yen SS
    Fertil Steril; 1990 Nov; 54(5):805-10. PubMed ID: 2226914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of estradiol supplementation during the luteal phase on mouse endometrial expression of leukaemia inhibitory factor and pinopodes in controlled ovarian stimulation cycles].
    Zhang CL; Xie JK; Zhang SD; Qiao YH
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):937-41. PubMed ID: 19134335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists.
    Saadat P; Boostanfar R; Slater CC; Tourgeman DE; Stanczyk FZ; Paulson RJ
    Fertil Steril; 2004 Jul; 82(1):167-71. PubMed ID: 15237007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
    Olivennes F
    J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human endometrial maturation is markedly improved after luteal supplementation of gonadotrophin-releasing hormone analogue/human menopausal gonadotrophin stimulated cycles.
    Bourgain C; Smitz J; Camus M; Erard P; Devroey P; Van Steirteghem AC; Kloppel G
    Hum Reprod; 1994 Jan; 9(1):32-40. PubMed ID: 8195348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression.
    Bermejo A; Cerrillo M; Ruiz-Alonso M; Blesa D; Simón C; Pellicer A; Garcia-Velasco JA
    Fertil Steril; 2014 Jan; 101(1):138-146.e3. PubMed ID: 24182413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function.
    DiLuigi AJ; Nulsen JC
    Curr Opin Obstet Gynecol; 2007 Jun; 19(3):258-65. PubMed ID: 17495643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
    Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of luteal-phase support on endometrial L-selectin ligand expression after recombinant follicle-stimulating hormone and ganirelix acetate for in vitro fertilization.
    Vlahos NF; Lipari CW; Bankowski B; Lai TH; King JA; Shih IeM; Fragakis K; Zhao Y
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4043-9. PubMed ID: 16868054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.